342 assets in Glioblastoma

Therapeutic assets addressing Glioblastoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Tocilizumab Glioblastoma	National Cancer Institute (NCI)	P2	CCC (53)
cc-115 Glioblastoma	Patrick Wen, MD	P2	CCC (52)
Lonafarnib Glioblastoma	Duke University	P2	CCC (52)
Memantine Glioblastoma	University of Zurich	P2	CCC (52)
Relatlimab Glioblastoma	Duke University	P2	CCC (52)
Ruxolitinib Glioblastoma	Baptist Health South Florida	P2	CCC (52)
Silevertinib Glioblastoma	Black Diamond Therapeutics, Inc.	P2	CCC (52)
Sitagliptin Glioblastoma	Kailin Yang, MD, PhD	P2	CCC (52)
Tamoxifen Glioblastoma	University of Rochester	P2	CCC (52)
Tlx-101-Tx Glioblastoma	Telix Pharmaceuticals (Innovations) Pty Limited	P3	CCC (52)
Adv/Hsv-Tk Glioblastoma	The Methodist Hospital Research Institute	P1/2	CCC (51)
Mannitol Glioblastoma	Northwell Health	P2	CCC (51)
Ucpvax Glioblastoma	Centre Hospitalier Universitaire de Besancon	P2	CCC (51)
Copper Glioblastoma	Olympion Medical Center	P2	CCC (50)
Dichloroacetate Glioblastoma	University of Florida	P2	CCC (50)
Egfr/B7H3 Car-T Glioblastoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P1/2	CCC (50)
m032 Glioblastoma	University of Alabama at Birmingham	P1/2	CCC (50)
Pvsripo (Chimeric Poliovirus (Pv), Consisting Of The Type-1 Sabin Vaccine Strain Carrying A Foreign Internal Ribosome Entry Site (Ires) From Human Rhinovirus Type-2) (Hrv2) Glioblastoma	Darell Bigner	P2	CCC (50)
vt1021 Glioblastoma	Global Coalition for Adaptive Research	P2/3	CCC (50)
5-Flucytosine Glioblastoma	CHA University	P1/2	CCC (49)
Fludarabine Glioblastoma	Beijing Biotech	P1/2	CCC (49)
msc11fcd Glioblastoma	CHA University	P1/2	CCC (49)
Sulfasalazine Glioblastoma	University of Zurich	P1/2	CCC (49)
2141-v11 Glioblastoma	Darell Bigner	P1/2	CCC (48)
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE Glioblastoma	Universidad Central del Caribe	P2	CCC (48)
4scar dll3 t cells Glioblastoma	Shenzhen Geno-Immune Medical Institute	P1/2	CCC (48)
Apixaban Glioblastoma	University of Vermont Medical Center	P2	CCC (48)
bpm31510 Glioblastoma	BPGbio	P2	CCC (48)
Clindamycin Glioblastoma	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Cobolimab Glioblastoma	GlaxoSmithKline	P1/2	CCC (48)
d2c7-it Glioblastoma	Darell Bigner	P1/2	CCC (48)
db107-fc Glioblastoma	University of California, San Francisco	P1/2	CCC (48)
db107-rrv Glioblastoma	University of California, San Francisco	P1/2	CCC (48)
Dordaviprone Glioblastoma	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Dostarlimab Glioblastoma	GlaxoSmithKline	P1/2	CCC (48)
Dual Antibody B Glioblastoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	CCC (48)
erc1671 Glioblastoma	Epitopoietic Research Corporation	P2	CCC (48)
Fluzoparib Glioblastoma	Tongji Hospital	P2	CCC (48)
Igv-001 Cell Immunotherapy Glioblastoma	Imvax	P2	CCC (48)
Incagn01876 Glioblastoma	University of Pennsylvania	P2	CCC (48)
Kenacort Glioblastoma	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Nabiximols Glioblastoma	University of Birmingham	P2	CCC (48)
Neratinib Glioblastoma	Patrick Wen, MD	P2	CCC (48)
Pd-L1 T-Hank Glioblastoma	ImmunityBio, Inc.	P2	CCC (48)
Pemigatinib Glioblastoma	Incyte Corporation	P2	CCC (48)
Phytonadione, (E)-(±)- Glioblastoma	BPGbio	P2	CCC (48)
Pramine Glioblastoma	The University of Texas Health Science Center at San Antonio	P2	CCC (48)
qbs10072s Glioblastoma	Patrick Wen, MD	P2	CCC (48)
Sonala-001 Glioblastoma	SonALAsense, Inc.	P1/2	CCC (48)
tng456 Glioblastoma	Tango Therapeutics, Inc.	P1/2	CCC (48)

Showing 101 to 150 of 342 assets

PreviousPage 3 of 7Next